Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.

• The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m²), cisplatin (90 mg/m²), and doxorubicin (75 mg/m²). 3 cycles were administered postoperatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m²) as a salvage strategy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Ortopedi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Orthopaedics (hsv//eng)

Nyckelord

Adolescent

Adult

Antibiotics

Antineoplastic

administration & dosage

Antineoplastic Agents

administration & dosage

Antineoplastic Combined Chemotherapy Protocols

administration & dosage

Bone Neoplasms

drug therapy

mortality

surgery

Chemotherapy

Adjuvant

Child

Cisplatin

administration & dosage

Doxorubicin

administration & dosage

Female

Finland

Follow-Up Studies

Humans

Ifosfamide

administration & dosage

Male

Methotrexate

administration & dosage

Norway

Osteosarcoma

drug therapy

mortality

surgery

Sweden

Treatment Outcome

Young Adult

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)